Agios Pharmaceuticals, Inc.AGIO

Agios Pharmaceuticals entered the week with a shiny FDA approval for Pyrukynd (mitapivat), its first-in-class activator for pyruvate kinase deficiency, and exited the quarter with a net loss of $99.1 million on revenue of $20.7 million. The company’s press release hails “net product revenue from U.S. sales of $18.8 million” for Q1 2026 versus $8.7 million a year earlier, while ex-U.S. sales added another $1.9 million. Those are real numbers, even if they look thin next to the $118.9 million of operating cash used in the same period. The math is simple: burn faster than you earn, and even an orphan drug can’t hide the arithmetic.

The product itself is Pyrukynd (mitapivat), an oral PK activator for adults with pyruvate kinase deficiency, a rare genetic disorder that turns red blood cells into premature retirees before their time. Agios markets the pill as the first FDA-approved therapy for the condition, which is good news for the roughly one in 200,000 people estimated to have it. The company pairs the drug with patient support programs and a global managed access program in the EU, the usual machinery for rare-disease launches. On the evidence rail, that machinery exists; on the cash rail, it is currently running on borrowed time and borrowed money.

SEC filings for the quarter ending March 31, 2026, show revenue of $20.7 million, a net loss of $99.1 million, operating loss of $110.0 million, and diluted EPS of -$1.69 on 58.8 million shares. Cash and equivalents stood at $113.6 million, liabilities at $75.9 million, and stockholders’ equity at $1.11 billion, while R&D spend clocked $81.1 million and inventory rose $2.2 million to $35.1 million. The company also paid $769,000 for property, plant, and equipment-about enough to buy a modest MRI or two.

For a quick look at the share price action, the SEC submissions index provides the official filing trail, while the companyfacts JSON shows the latest XBRL tagged disclosures. Neither source gives a price chart, so any attempt to read candles here would be the purest fiction. If you need a chart, the product news rail and clinical trial registries are the only official sources on offer; the rest is investor theatre.

What changed this quarter is the shift from pipeline story to commercial story: Agios now sells a real product with real revenue, but the revenue base is still embryonic, the burn is large, and the company’s cash runway remains the single most important variable. What remains unproven is whether the revenue trajectory can outgrow the burn rate without another financing round. What would deepen this file next is a detailed breakdown of patient starts, payer access wins, and a clear cash runway disclosure in the next 10-Q or investor presentation.